Nuvalent, Inc. (NUVL)
|Net Income (ttm)||-26.70M|
|Day's Range||33.00 - 36.89|
|52-Week Range||17.00 - 40.82|
|Price Target||42.00 (+26.5%)|
|Est. Earnings Date||Nov 15, 2021|
Nuvalent is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We focus our discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, we focus on “clinically proven” kinase targets. We develop innovative small molecules that are designed to overcome the limitations of those existing therapies. By prioritizing target selectivity, we believe our drug candidates have ... [Read more...]
Financial PerformanceFinancial Statements
Nuvalent Announces Business and Program Highlights and Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass., Sept. 8, 2021 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cance...
With the trading day more than halfway over, the broad markets had a roaring start to the week with the S&P 500 and Nasdaq hitting record intraday highs.
CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announce...
/PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer,...
Nuvalent has brought in $185 million through two funding rounds since launching in January, but the precision cancer biotech wants more: an IPO. Cambridge, Massachusetts-based Nuvalent filed Wednesday f...
Deerfield Capital's latest cancer venture is raring to hit the public markets, just six months after emerging from stealth.
Nuvalent, Inc. has filed to go public with an IPO on the NASDAQ.